No Data
No Data
Where Nevro Stands With Analysts
Nevro Is Maintained at Hold by Truist Securities
Truist Financial Maintains Nevro(NVRO.US) With Hold Rating, Cuts Target Price to $4.7
Nevro Price Target Lowered to $4.70 From $7 at Truist
Express News | Nevro Corp : Truist Securities Cuts Target Price to $4.7 From $7
Pain Management Devices Global Analysis Report 2024-2034 Featuring Abbott Laboratories, Boston Scientific, Medtronic, Nevro, Baxter, OMRON, Stryker, Teleflex, ICU Medical, AtriCure, and Zynex
Unlock the Full List